• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    8/22/22 2:30:30 PM ET
    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email

     

    Gainers

    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares increased by 90.9% to $0.41 during Monday's regular session. Trading volume for this security as of 13:30 EST is 78.6 million, which is 12691.0% of its average full-day volume over the last 100 days. The company's market cap stands at $16.2 million.
    • Minerva Neurosciences (NASDAQ:NERV) shares increased by 46.53% to $4.55. As of 13:30 EST, Minerva Neurosciences's stock is trading at a volume of 12.7 million, which is 1639.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.2 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares increased by 42.72% to $1.57. Trading volume for this security as of 13:30 EST is 41.7 million, which is 9095.5% of its average full-day volume over the last 100 days. The company's market cap stands at $315.5 million.
    • Cabaletta Bio (NASDAQ:CABA) stock moved upwards by 34.58% to $1.79. Trading volume for Cabaletta Bio's stock is 11.6 million as of 13:30 EST. This is 5274.9% of its average full-day volume over the last 100 days. The company's market cap stands at $51.9 million.
    • Signify Health (NYSE:SGFY) stock rose 31.83% to $27.95. As of 13:30 EST, Signify Health's stock is trading at a volume of 15.2 million, which is 842.0% of its average full-day volume over the last 100 days. The company's market cap stands at $6.5 billion.
    • BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 24.15% to $0.56. As of 13:30 EST, BIMI Intl Medical's stock is trading at a volume of 2.0 million, which is 93.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.9 million.

    Losers

    • Amarin Corp (NASDAQ:AMRN) stock fell 20.6% to $1.25 during Monday's regular session. The current volume of 5.1 million shares is 142.1% of Amarin Corp's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $506.0 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares fell 18.69% to $0.74. As of 13:30 EST, Aeglea BioTherapeutics's stock is trading at a volume of 3.7 million, which is 176.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $45.2 million.
    • Burning Rock Biotech (NASDAQ:BNR) stock decreased by 16.84% to $2.93. As of 13:30 EST, Burning Rock Biotech's stock is trading at a volume of 1.1 million, which is 144.0% of its average full-day volume over the last 100 days. The company's market cap stands at $307.9 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock decreased by 16.39% to $1.48. As of 13:30 EST, this security is trading at a volume of 90.0K shares, making up 72.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $26.1 million. The company's, Q2 earnings came out 4 days ago.
    • SmileDirectClub (NASDAQ:SDC) shares decreased by 16.22% to $1.36. Trading volume for SmileDirectClub's stock is 9.4 million as of 13:30 EST. This is 230.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $164.4 million.
    • Endo International (NASDAQ:ENDP) shares decreased by 15.91% to $0.34. Trading volume for Endo International's stock is 41.6 million as of 13:30 EST. This is 68.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $79.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $AMRN
    $ANPC
    $ARDS

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Cabaletta Bio Inc.
    $CABA
    10/10/2025$14.00Buy
    Jefferies
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    Summit Therapeutics Inc.
    $SMMT
    6/11/2025$12.00Underperform
    Leerink Partners
    More analyst ratings

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

    BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ETWebcast:https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/SKrutqyvQVtnaKJDseE6uU   If you are interested in meeting with the Minerva team during the conference, please reach

    3/4/26 7:00:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

    Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with di

    3/2/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Present at Upcoming Investor Conferences

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday, March 10, 2026 Investor meetings only Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.

    2/26/26 6:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    SEC Filings

    View All

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:20:33 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:15:07 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/10/26 5:15:32 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Business Officer Das Arun

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    3/2/26 7:28:34 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by General Counsel Gerard Michael

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    3/2/26 7:27:54 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President, Science & Tech. Binder Gwendolyn

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    3/2/26 7:26:00 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Cabaletta Bio with a new price target

    Jefferies resumed coverage of Cabaletta Bio with a rating of Buy and set a new price target of $14.00

    10/10/25 8:36:11 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Leadership Updates

    Live Leadership Updates

    View All

    Burning Rock Announces Results of 2025 Annual General Meeting

    GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to d

    12/22/25 11:04:44 PM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 3:36:55 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $AMRN
    $ANPC
    $ARDS
    Financials

    Live finance-specific insights

    View All

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care